Raghu Nandan

Yesterday i met a founder who graduated from Yale and came back to India to build a biotech company. They're trying to make vaccines for liver and pancreatic cancer and other infectious diseases that kill 80-90% of patients within five years. Team of 100+ scientists, AI engineers and medical specialists based in India who got research grants from some of the world's most credible institutions. But they're unable to raise VC money from Indian investors because most can't underwrite a 7-10 year bet on deep science. So they're moving the legal entity outside India to access international investors. Another issue is the slow regulatory framework. India holds 17% of the world's population and 20% of its disease burden, but runs barely 1.2% of global clinical trials. Getting regulatory approval for a clinical trial takes a few years sometimes versus a few weeks in the US or China. So this company is doing their first phase of trials outside of India. We need two things to change. First on funding, we need a dedicated health fund which is government backed with a 10-15+ year horizon, willing to take the early risk that commercial VCs can't model. This is something we're trying to do at Rainmatter across all our investments. If we want a better healthcare , we need a system to support innovators. On regulation, maybe add more staffing bandwidth and bring updates to clinical frameworks at CDSCO with a 30 day timeline and a parallel ethics review that moves fast. We've the talent and science here and the patients are here. What's missing is the institutional will to back them. We just keep making it someone else's problem to fund. It's shouldn't be acceptable that Indian talent runs the science but India won't own the upside.

Unreal hyping of "Hyderabad dosa" on social media - whatever it is, its some new creation. Similar to Ahmedabad dosa or Delhi dosa. Dosa isn't traditional to Hyderabad region. 50+ years ago nobody there made and ate it at home. Dosa is native to Karnataka & Tamil Nadu.

We also want to inform you that the brown dog, which had recently bitten two individuals and shown signs of aggression, has been carefully handled, calmed, and gently returned to its familiar area. Our approach remains rooted in care, safety, and responsible management. (3/6)

We would like to share an important update and clarification regarding the dogs around Delhi Airport. (1/6)

Bro got premium membership of life 🤌🤍

Today, India takes a defining step in its civil nuclear journey, advancing the second stage of its nuclear programme. The indigenously designed and built Prototype Fast Breeder Reactor at Kalpakkam has attained criticality. This advanced reactor, capable of producing more fuel than it consumes, reflects the depth of our scientific capability and the strength of our engineering enterprise. It is a decisive step towards harnessing our vast thorium reserves in the third stage of the programme. A proud moment for India. Congratulations to our scientists and engineers.